However, it should be noted that that the inhibition of tumor growth, together with the suppression of MMPs, COX-2, M2 polarization, VEGF, and the number of blood vessels, combined with the enhancement of the immunopotentiating blood biomarkers such as lymphocyte-to-monocyte ratio (LMR) and the reduction in the polymorphonuclear/mononuclear (P/M) ratio, provides a strong basis for further preclinical research. The gene discussed is VEGFA; the disease is neoplasm.